MPO and neoplasm: More importantly, further in vivo experiments demonstrated that S428‐1145 (25 mg/kg, once daily) significantly inhibited tumour growth (Figure 9Q–S) and downregulated key NETs biomarkers such as Cit‐H3 and MPO in tumour tissues (Figure 9T,U).